View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
Avandia, the popular type 2 diabetes drug, will have a revised black-box label warning of its associated heart attack risks, announced GlaxoSmithKline, the drug's maker. Despite mandating this labeling change, FDA officials aren't seeking to have rosiglitazone (Avandia) pulled from the market because evidence of the drug's heart attack risk is inconclusive. According to an FDA official, there simply isn't enough evidence to indicate that heart attack risks are any higher with Avandia than other type 2 diabetes drugs.
The FDA advises health care providers to monitor patients with type 2 diabetes who are at cardiac risk and are taking Avandia. For more information about the labeling changes, visit http://www.fda.gov.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top